Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Regeneron is buying back $1 billion in stock, but hell has not yet frozen over

  • Damian Garde

By Damian Garde Nov. 6, 2019

Reprints
Len Schleifer
Len Schleifer, founder of Regeneron. Mike Groll/AP

A version of this story appeared in STAT’s biotech newsletter, The Readout. Sign up here.

Regeneron Pharmaceuticals yesterday announced it would spend $1 billion buying its own stock, a move that was both unremarkable and remarkable at the same time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Long after the fire of a Covid-19 infection, mental…
Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder
Some medical students still think black patients feel less…
Some medical students still think black patients feel less pain than whites
As AI promises to revolutionize medical note-taking, concerns mount…
As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm
Could a fight over cost-effectiveness upend Medicare drug price…
Could a fight over cost-effectiveness upend Medicare drug price negotiation before it’s begun?
Novartis data set up multibillion-dollar battle over breast cancer…
Novartis data set up multibillion-dollar battle over breast cancer drugs

Recommended Stories